Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 163 of the 164 references it cites were found in a registry or an index; 10 of the 18 sources its claims cite were checked for support.

GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits

Open access

Abstract

GLP-1 receptor agonists were initially developed to treat type 2 diabetes and have had a transformative effect on its therapy, and are highly effective for glycaemic control, with the added benefit of bodyweight reduction and a low risk of causing hypoglycaemia. GLP-1 receptor agonists reduce risks for major adverse cardiovascular events (eg, non-fatal myocardial infarction, stroke, and cardiovascular death), and the risk of admission to or treatment within hospital for heart failure. These drugs reduce albuminuria and slow the decline in estimated glomerular filtration rate over time, therefore delaying or preventing kidney failure. Furthermore, GLP-1 receptor agonists (eg, liraglutide and semaglutide) and the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor co-agonist tirzepatide have been approved for treatment of obesity, with clinical trials establishing benefits for various obesity-related conditions: prevention of type 2 diabetes; risk for major adverse cardiovascular events; heart failure, especially with preserved ejection fraction; regression of steatosis and prevention of fibrosis in steatotic liver disease; and symptomatic improvements in obstructive sleep apnoea and knee osteoarthritis. Current developments include the exploration of novel indications (eg, neurodegenerative diseases and substance use disorders) with suggestive evidence of efficacy, and the development of small-molecule GLP-1 receptor agonists for oral treatment to improve convenience. Dual (ie, GLP-1-glucagon and GLP-1-amylin) and triple (ie, GIP-GLP-1-glucagon) receptor agonists activating multiple receptors promise greater efficacy than mono-agonists, especially for weight loss. However, some clinical development programmes have a high burden of adverse gastrointestinal events, and dose-escalation regimens should be optimised to reach acceptable tolerability.

Overview

CoChat Summary

TL;DR

This review summarizes how GLP-1 receptor agonists and newer incretin-based drugs have become established treatments for type 2 diabetes and obesity, with benefits extending to cardiovascular, kidney, and several obesity-related outcomes. It also highlights next-generation dual/triple agonists and oral agents that may improve efficacy, but notes that tolerability and safety remain important issues.

Key findings

  • Currently available GLP-1 receptor agonists and tirzepatide are described as “highly efficacious and safe” for hyperglycaemia in type 2 diabetes, and some agents produce substantial weight loss in people with overweight or obesity.
  • In people with overweight or obesity and established cardiovascular disease without diabetes, semaglutide reduced MACE in SELECT with HR 0.80 (95% CI 0.72–0.90); in the same trial, reductions were also reported for heart-failure-related events (18%), all-cause mortality (19%), coronary revascularisation (23%), and a kidney composite endpoint (22%), though these were not statistically significant under hierarchical testing.
  • In the FLOW kidney outcomes trial in type 2 diabetes with CKD, semaglutide reduced the composite primary kidney outcome by 24% (HR 0.76, 0.66–0.88), slowed eGFR decline (annual slope difference 1.16 mL/min per 1.73 m²), and reduced MACE (HR 0.82, 0.68–0.98) and all-cause mortality (HR 0.80, 0.67–0.95).
  • For obesity-related conditions, the paper reports benefits including prevention of progression to type 2 diabetes by 66–93% vs placebo, and improvements in MASLD, HFpEF, obstructive sleep apnoea, and knee osteoarthritis.

Methods

  • Narrative review of incretin-based medications, focusing on GLP-1 receptor agonists and newer mono-, dual-, and triple-agonist therapies.
  • Literature was gathered by searching PubMed for English, German, and French papers from database inception to Oct 13, 2025, plus additional literature collected by the authors since 1987.
  • The review synthesizes clinical trial evidence on glycaemic control, weight loss, cardiovascular outcomes, kidney outcomes, adverse events, and selected obesity-associated conditions.

Limitations

  • The paper does not report a formal systematic review or meta-analysis protocol, so the evidence synthesis is narrative and may be selective.
  • The search was limited to PubMed and to papers in English, German, and French (stated in the paper), which may omit relevant studies in other languages or indexed elsewhere.
  • Because this is a review, most conclusions depend on previously published trials; the text also notes that some newer agents and indications still require large-scale phase 3 trials to establish clinical benefits, safety, and tolerability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(25)02105-1

Cites

163 of 164 references verified0 citation errors · 1 not checkable

Statistics

Nothing to recompute.

Figures

Figure 2 Results for reductions in MACE from individual cardiovascular outcomes studies (A and C) and for various outcomes from a meta-analysis of cardiovascular outcomes studies (B) in populations with type 2 diabetes and overweight or obesity with ASCVD populations with type 2 diabetes are shown for the primary endpoint (MACE), the components of MACE (ie, fatal and non-fatal myocardial infarction or stroke and
Figure 2 Results for reductions in MACE from individual cardiovascular outcomes studies (A and C) and for various outcomes from a meta-analysis of cardiovascular outcomes studies (B) in populations with type 2 diabetes and overweight or obesity with ASCVD populations with type 2 diabetes are shown for the primary endpoint (MACE), the components of MACE (ie, fatal and non-fatal myocardial infarction or stroke andCC-BY · From the PDF
Figure 3 Effect of GLP-1 receptor agonists on composite kidney outcomes in cardiovascular and kidney outcomes trials in populations with type 2 diabetes HRs ( vs placebo) are shown with 95% CIs and p values indicating the significance of the difference to placebo treatment. Original results were taken from the primary publications: LEADER, 20,41 SUSTAIN-6, 19 AWARD-7, 42,43 REWIND, 622,44 AMPLITUDE-O, 24 and FLOW. 26 Results from the FLOW trial regarding a composite of kidney-specific components of the primary outcome (excluding cardiovascular death) are depicted for better comparability with other studies. This was not the primary outcome of that study. In the LEADER, SUSTAIN-6, and SOUL trials, chronic kidney disease with an estimated glomerular filtration rate of less than 60 mL/min per 1·73 m² body surface was taken as an equivalent of established cardiovascular disease. The ELIXA, 17 EXSCEL, 20 HARMONY-Outcomes, 21 PIONEER-6, 23 and SELECT 28 trials (for people with obesity with established atherosclerotic cardiovascular disease at baseline) did not report these outcomes. Details of the components of composite kidney outcomes in the individual trials are available in the appendix (p 9). In most trials, the primary outcome included cardiovascular death; in this figure, only kidneyspecific composite outcomes are depicted. HR=hazard ratio. NR=not reported.
Figure 3 Effect of GLP-1 receptor agonists on composite kidney outcomes in cardiovascular and kidney outcomes trials in populations with type 2 diabetes HRs ( vs placebo) are shown with 95% CIs and p values indicating the significance of the difference to placebo treatment. Original results were taken from the primary publications: LEADER, 20,41 SUSTAIN-6, 19 AWARD-7, 42,43 REWIND, 622,44 AMPLITUDE-O, 24 and FLOW. 26 Results from the FLOW trial regarding a composite of kidney-specific components of the primary outcome (excluding cardiovascular death) are depicted for better comparability with other studies. This was not the primary outcome of that study. In the LEADER, SUSTAIN-6, and SOUL trials, chronic kidney disease with an estimated glomerular filtration rate of less than 60 mL/min per 1·73 m² body surface was taken as an equivalent of established cardiovascular disease. The ELIXA, 17 EXSCEL, 20 HARMONY-Outcomes, 21 PIONEER-6, 23 and SELECT 28 trials (for people with obesity with established atherosclerotic cardiovascular disease at baseline) did not report these outcomes. Details of the components of composite kidney outcomes in the individual trials are available in the appendix (p 9). In most trials, the primary outcome included cardiovascular death; in this figure, only kidneyspecific composite outcomes are depicted. HR=hazard ratio. NR=not reported.CC-BY · From the PDF

Verification

Claims the paper makes

6 Valid · 2 Not valid · 4 Not checked · 11 Own results and interpretations

18 more claims · 2 with their cited sources checked

Create a free account to see all 23 claims and every source verdict.

See all claims — free account

Citations

Cites

Show all 150 references

Cited by

See all 123

Metadata

Authors
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M.
Affiliations
  • Universitätsmedizin Greifswald (DE)
  • University of Washington (US)
  • Helmholtz Munich (DE)
Corresponding author
Nauck, Michael A
Venue
The Lancet
Publisher
Elsevier BV
Published
2026-02
Volume
407
Issue
10531
Pages
892-908
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W7124314989
Cited by
123
References
150
Citations by year
2026: 123
FWCI
130.49
Type
journal article
Language
en
Update notices
erratum (2026-03-14)
Open access
Licence
Locations
  • The Lancet (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • Centers for Disease Control and Prevention
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
GLP-1 receptor agonists, incretin-based therapy, type 2 diabetes, obesity, cardiovascular risk, heart failure, albuminuria, renal function decline, tirzepatide, liraglutide, semaglutide, preserved ejection fraction, nonalcoholic steatohepatitis, obstructive sleep apnea, knee osteoarthritis, gastrointestinal adverse effects, weight loss, neurodegenerative diseases, substance use disorders
MeSH terms
Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Hypoglycemic Agents, Obesity, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-25 (prompt extract-v2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. https://app.cochat.ai/papers/10.1016/s0140-6736(25)02105-1
The paper
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026). GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. The Lancet. https://doi.org/10.1016/s0140-6736(25)02105-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.